As of today (2026-07-01), the Forward Annual Dividend Yield of GlaxoSmithKline Pakistan is 4.59%.
As of today (2026-07-01), the Trailing Annual Dividend Yield of GlaxoSmithKline Pakistan is 4.59%.
KAR:GLAXO's Forward Dividend Yield % is ranked better than 84.33% of 504
companies
in the Drug Manufacturers industry
Industry Median: 2.08
vs KAR:GLAXO: 4.59
During the past 3 years, the average Dividends Per Share Growth Rate was 28.90% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of GlaxoSmithKline Pakistan was 37.00% per year. The lowest was -22.80% per year. And the median was 3.60% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
GlaxoSmithKline Pakistan Forward Dividend Yield % Related Terms
KAR:GLAXO vs ZTS, UTHR, VTRS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
GlaxoSmithKline Pakistan Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
PKR 12.000000
2026-04-24
2026-04-24
2026-05-06
Cash Dividend
semi-annually
PKR:PKR 1.000000
PKR 5.000000
2025-09-05
2025-09-08
2025-09-19
Cash Dividend
semi-annually
PKR:PKR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 4.59% mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Forward Dividend Yield % of 4.59% as of Jul. 01, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on GlaxoSmithKline Pakistan and its competitors. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #79 out of 504 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is GlaxoSmithKline Pakistan's Forward Dividend Yield % too high?
GlaxoSmithKline Pakistan's current Forward Dividend Yield % is 4.59%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.08. GlaxoSmithKline Pakistan's value of 4.59% is 120.7% above this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #79 out of 504 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #79 out of 504 companies for Forward Dividend Yield %. This places GlaxoSmithKline Pakistan in the top 16% of its industry — outperforming the majority of peers. The industry median Forward Dividend Yield % is 2.08. GlaxoSmithKline Pakistan's value of 4.59% is 120.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.08, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current Forward Dividend Yield % of 4.59% is 120.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current Forward Dividend Yield % is 4.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current Forward Dividend Yield % is 4.59% and 120.7% above the Drug Manufacturers industry median of 2.08. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Forward Dividend Yield % is 4.59% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
Forward Dividend Yield %: 4.59%
GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
Industry Position: 120.7% above the Drug Manufacturers median (#79 of 504)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 